Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906245 | 0.88 | KDM4E (0.51) | IKBKBFFAR1MAPTPDGFRBKDR | |
| SCHEMBL1479638 | 0.84 | GRM5 (0.56) | GRM5MAPTSIRT2SIRT1SIRT3 | |
| SCHEMBL16782152 | 0.83 | ATM (0.47) | IKBKBFFAR1GRM5MAPTPDGFRB | |
| Hydrochloric Acid SCHEMBL1476861 | 0.83 | GRM5 (0.55) | GRM5MAPTSIRT2SIRT1SIRT3 | |
| SCHEMBL18340664 | 0.81 | TSHR (0.56) | FFAR1MAPTSIRT2SIRT1SIRT3 | |
| SCHEMBL16782072 | 0.80 | KDR (0.64) | PDGFRBKDR | |
| SCHEMBL16782074 | 0.79 | KDR (0.44) | FFAR1MAPTPDGFRBKDR | |
| SCHEMBL22384748 | 0.79 | KDR (0.45) | IKBKBFFAR1GRM5PDGFRBKDR | |
| SCHEMBL1028239 | 0.76 | MAPT (0.45) | IKBKBFFAR1GRM5MAPTPDGFRB | |
| SCHEMBL18339878 | 0.76 | IKBKB (0.60) | IKBKBMAPTPDGFRBKDRSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3080105-B1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20180194731-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194731-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194731-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-07-12 | — | — | US | disclosed |
| US-9951019-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951019-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951019-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160376238-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-12-29 | — | — | US | disclosed |
| US-20160376238-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376238-A1 | THERAPEUTIC COMPOUNDS | SIRT2, SIRT1, SIRT3 | IKBKB 1126/4885FFAR1 2698/4885GRM5 4006/4885 |
| US-20180194731-A1 | THERAPEUTIC COMPOUNDS | SIRT2, SIRT1, SIRT3 | IKBKB 1126/4885FFAR1 2698/4885GRM5 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.